Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology
Abstract
Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti-VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off-label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti-VEGF agents to achieve and maintain effective...
Paper Details
Title
Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology
Published Date
Mar 10, 2021
Volume
9
Issue
2
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History